RxDoctor Payments Data

Praveen Mullangi, MD

Infectious Disease · Springfield, ILNPI 1508056987

Payments from drug & device makers

$6,540in general payments, 2019–2025

Across 154 payments — averaging $42.47 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$4K
  • Viiv Healthcare Company$937
  • Insmed, Inc.$474
  • Aimmune Therapeutics, Inc.$383
  • Shionogi Inc$355
  • EMD Serono, Inc.$190
  • plus $418 from 10 others

What the payments were for

  • Speaking & faculty fees$3,30050%
  • Travel & lodging$1022%
  • Food & beverage$2,89444%
  • Education$2444%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,540 in reported general payments places this provider in the 80th percentile of 368 infectious disease providers in Illinois.

See all infectious disease providers in Illinois

Medicare billing

Part B allowed, 2024
$153,415
Medicare patients
327
Services billed
1,691

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GenvoyaElviteg/Cob/Emtri/Tenof Alafen72$293,080
ArikayceAmikacin Liposomal/Neb.Accessr18$274,747
BiktarvyBictegrav/Emtricit/Tenofov Ala29$126,648
Daptomycin76$71,524
DescovyEmtricitabine/Tenofov Alafenam30$69,225
OdefseyEmtricitab/Rilpiviri/Tenof Ala18$64,631
PrezcobixDarunavir/Cobicistat15$42,810
TivicayDolutegravir Sodium15$38,845
PifeltroDoravirine12$24,588
Posaconazole22$14,155
ErtapenemErtapenem Sodium32$12,684
Darunavir26$11,512
Vancomycin Hcl82$11,132
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam29$10,517
Cefepime Hcl63$10,058

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadGenvoya, Biktarvy, Descovy$29$488,954131 claims
Insmed, Inc.Arikayce$474$274,74718 claims
Viiv Healthcare CompanyTivicay$937$38,84515 claims
MerckPifeltro$66$24,58812 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 368 infectious disease providers in Illinois.

Other infectious disease in Springfield

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →